Bamco Inc. NY Makes New Investment in Roivant Sciences Ltd. $ROIV

Bamco Inc. NY purchased a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) in the 3rd quarter, HoldingsChannel reports. The fund purchased 105,000 shares of the company’s stock, valued at approximately $1,589,000.

A number of other institutional investors have also modified their holdings of ROIV. Penn Davis Mcfarland Inc. grew its stake in Roivant Sciences by 10.1% during the 3rd quarter. Penn Davis Mcfarland Inc. now owns 1,862,088 shares of the company’s stock worth $28,173,000 after buying an additional 170,456 shares during the last quarter. Valeo Financial Advisors LLC acquired a new position in Roivant Sciences during the 2nd quarter valued at about $1,145,000. TD Asset Management Inc raised its stake in Roivant Sciences by 94.7% in the third quarter. TD Asset Management Inc now owns 316,200 shares of the company’s stock valued at $4,784,000 after buying an additional 153,800 shares during the last quarter. New York State Common Retirement Fund raised its stake in Roivant Sciences by 25.4% in the third quarter. New York State Common Retirement Fund now owns 229,037 shares of the company’s stock valued at $3,465,000 after buying an additional 46,344 shares during the last quarter. Finally, Franklin Resources Inc. acquired a new stake in Roivant Sciences in the second quarter worth about $997,000. 64.76% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ROIV. Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Guggenheim lifted their target price on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. The Goldman Sachs Group boosted their target price on shares of Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Leerink Partners upped their price target on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a report on Wednesday, March 4th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $28.81.

Insider Buying and Selling at Roivant Sciences

In related news, insider Mayukh Sukhatme sold 339,441 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $26.47, for a total transaction of $8,985,003.27. Following the completion of the transaction, the insider owned 19,148,664 shares of the company’s stock, valued at $506,865,136.08. This trade represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $26.49, for a total value of $5,298,000.00. Following the transaction, the chief executive officer owned 1,654,597 shares of the company’s stock, valued at $43,830,274.53. The trade was a 10.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 7,356,987 shares of company stock valued at $184,757,294 over the last quarter. Insiders own 10.80% of the company’s stock.

Roivant Sciences Trading Up 0.8%

Shares of NASDAQ:ROIV opened at $28.28 on Tuesday. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $30.33. The company has a market cap of $20.24 billion, a PE ratio of -24.17 and a beta of 1.17. The company’s 50 day moving average is $25.43 and its 200 day moving average is $20.87.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.